Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pyrimidine compounds as delta opioid receptor modulators

a technology of delta opioid receptor and pyrimidine, which is applied in the direction of drug compositions, biocide, cardiovascular disorders, etc., can solve the problems of difficulty in mentation, inability to concentrate, and not always pleasant experien

Inactive Publication Date: 2011-11-03
JANSSEN PHARMA NV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is directed to a compound of Formula I and its pharmaceutical composition for treating opioid receptor-modulated disorders such as inflammatory pain, centrally mediated pain, peripherally mediated pain, visceral pain, structural related pain, cancer / pain, soft tissue injury related pain, progressive disease related pain, neuropathic pain, and acute pain from acute injury. The compound of Formula I has the formula: wherein R1 is selected from the group consisting of phenyl optionally substituted with one to two substituents selected from the group consisting of C1-4alkyl, C1-4alkoxy, fluoro, chloro, cyano, and di(C1-4alkyl)aminocarbonyl; and Y is either ethyl, vinyl, or a bond. The compound can be used in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula I or a pharmaceutically acceptable salt form thereof. The invention also provides methods for making the compound and its pharmaceutical composition. The compound has the ability to bind to opioid receptors and has potential to treat opioid receptor-modulated disorders.

Problems solved by technology

However, when morphine in a selected pain-relieving dose is given to a pain-free individual, the experience is not always pleasant; nausea is common, and vomiting may also occur.
Drowsiness, inability to concentrate, difficulty in mentation, apathy, lessened physical activity, reduced visual acuity, and lethargy may ensue.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine compounds as delta opioid receptor modulators
  • Pyrimidine compounds as delta opioid receptor modulators
  • Pyrimidine compounds as delta opioid receptor modulators

Examples

Experimental program
Comparison scheme
Effect test

example 7

[0356]

[0357]A. (2S,4R)-4-Fluoro-2-(methoxy-methyl-carbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester (7b). HBTU (12.3 g, 32.3 mmol) was added in portions to a solution of Compound 7a (6.26 g, 26.9 mmol), N,O-dimethylhydroxylamine hydrochloride (3.15 g, 32.3 mmol), and DIEA (5.62 mL, 4.17 g, 32.3 mmol) in 60 mL of DMF at 0° C. After 15 min, the cooling bath was removed and the mixture was stirred 16 h at 20° C. EtOAc (200 mL) and saturated aqueous NH4Cl (100 mL) were added. The organic layer was separated, washed with saturated aqueous NaHCO3 (100 mL), and brine (100 mL), and dried over MgSO4. The solution was concentrated to give 7.7 g of off-white oil that was purified by flash column chromatography (SiO2), eluting with 10% MeOH / CH2Cl2, to yield Compound 7b (5.47 g, 74% yield). 1H-NMR (DMSO-d6): δ 5.29 (1H, dt), 4.70 (1H, dd), 3.50 (2H, m), 3.13 (3H, s), 2.69 (3H, s), 2.00 (2H, m), 1.34 (9H, s).

[0358]B. (2S,4R)-4-Fluoro-2-formyl-pyrrolidine-1-carboxylic acid tert-butyl ester...

example 8

[0359]

[0360]A. (2S,4R)-2-{[4-Bromo-2-(4-methoxy-phenoxy)-phenylamino]-methyl}-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (8a). A mixture of Compound 1d (1.18 g, 4.0 mmol), Compound 7c (1.33 g, 6.1 mmol), and 5 drops of HOAc in 10 mL of DCE was stirred for 5 min at 20° C. NaBH(OAc)3 (2.54 g, 12 mmol) was added in portions over a 5 min period and the mixture was stirred at 20° C. for 20 h. Saturated aqueous NH4Cl (25 mL) was added to the stirring mixture, followed by 100 mL of CH2Cl2 and 10 mL of water. The organic layer was separated and the aqueous layer was extracted with 50 mL of CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated to give 2 g of crude product. This material was purified by flash column chromatography (SiO2), eluting with a hexanes-EtOAc gradient, to yield Compound 8a (0.496 g, 25% yield). MS: m / z 495.0 / 497.0 (M+H)+.

[0361]B. (2S,4R)-2-{[4-(5-Cyano-pyridin-3-yl)-2-(4-methoxy-phenoxy)-phenylamino]-methyl}-4-fluoro-pyrrolidine-1-ca...

example 9

[0364]

[0365]A. 2-(S)-{[3-(4-Carbamoyl-phenoxy)-biphenyl-4-ylamino]-methyl}-pyrrolidine-1-carboxylic acid tent-butyl ester (9a). 20% aqueous NaOH (0.5 mL) and 30% aqueous H2O2 (0.4 mL) were added to a solution of compound 6f (0.040 g, 0.085 mmol) in 1.5 mL of EtOH and 1.5 mL of dioxane. The mixture was heated at 60° C. for 2 days. The reaction mixture was extracted with EtOAc, dried over MgSO4, and concentrated to give Compound 9a. MS: m / z 488.3 (M+H)+.

[0366]B. Cpd 29: (S)-4-{4-[(Pyrrolidin-2-ylmethyl)-amino]-biphenyl-3-yloxy}-benzamide. A mixture of Compound 9a, TFA, and CH2Cl2 was stirred at 20° C. for 2 h. After concentration, the residue was dissolved in CH3CN and purified by reverse phase HPLC to afford Cpd 29 as a TFA salt (0.015 g, 29% yield for 2 steps). 1H NMR (300 MHz, CD3OD): δ 7.87-7.89 (m, 2H), 7.33-7.49 (m, 5H), 7.18-7.19 (m, 2H), 7.00-7.06 (m, 3H), 3.84-3.95 (m, 1H), 3.44-3.57 (m, 2H), 3.28-3.35 (m, 2H), 1.98-2.28 (m, 3H), 1.72-1.82 (m, 1H); MS: m / z 387.9 (M+H)+.

[0367]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:wherein R1, R2, R3, Ra, and Y are defined herein.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application 61 / 256,412, filed on Oct. 30, 2009, which is incorporated by reference herein in its entirety.FIELD OF THE INVENTION[0002]The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of opioid modulated disorders.BACKGROUND OF THE INVENTION[0003]The term “opiate” has been used to designate pharmacologically active alkaloids derived from opium, e.g., morphine, codeine, and many semi-synthetic congeners of morphine. After the isolation of peptide compounds with morphine-like actions, the term opioid was introduced to refer generically to all drugs with morphine-like actions. Included among opioids are various peptides that exhibit morphine-like activity, such as endorphins, enkephalins and dynorphins. How...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377A61K31/506C07D413/14C07D403/14A61K31/496A61P19/02A61P25/06A61P25/04A61P13/10A61P17/00A61P1/00A61P35/00A61P29/00A61P25/16A61P25/24A61P25/32A61P9/00C07D401/14
CPCC07D401/14C07D403/12C07D403/14C07D413/14C07D403/04C07D417/14C07D401/04C07D239/47C07D409/14C07D405/14C07D401/12A61P1/00A61P1/04A61P1/12A61P1/16A61P11/00A61P11/02A61P11/04A61P13/00A61P13/02A61P13/08A61P13/10A61P15/00A61P15/12A61P17/00A61P17/02A61P17/04A61P19/00A61P19/02A61P21/00A61P25/00A61P25/02A61P25/04A61P25/06A61P25/16A61P25/24A61P25/28A61P25/30A61P25/32A61P29/00A61P35/00A61P9/00A61P9/10
Inventor COATS, STEVEN J.BIAN, HAIYANCAI, CHAOZHONGDECORTE, BART L.LIU, LIMACIELAG, MARK J.DAX, SCOTT L.PITIS, PHILIP M.CONNOLLY, PETER J.HE, WEI
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com